Thiogenesis Therapeutics, Corp.
TTIPF$23M
Micro CapNASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Apr 30, 2026
TomorrowMarket Overview
Stock performance and key metrics
TTIPF News
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
TTI-0102 Phase 2 Results Expected
Apr 30, 2026EstimatedTTI-010212
Primary completion for TTI-0102 trial (NCT06644534) in MELAS Syndrome
SourceDrug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TTI-0102 | Phase 2 | MELAS Syndrome | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply